vs
Side-by-side financial comparison of Aardvark Therapeutics, Inc. (AARD) and Altimmune, Inc. (ALT). Click either name above to swap in a different company.
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel targeted therapies for inflammatory, metabolic, and orphan diseases. It advances G-protein coupled receptor-targeting pipeline candidates, serving patient populations primarily in North America and global markets via R&D partnerships.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative immunotherapies, vaccines, and peptide-based therapies. Its pipeline covers infectious disease prevention, liver disease treatments, and metabolic disorder therapies, serving global biopharmaceutical and healthcare markets while advancing candidates through clinical trials.
AARD vs ALT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $0 | $26.0K |
| Net Profit | $-17.6M | — |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | — |
| Revenue YoY | — | 420.0% |
| Net Profit YoY | — | -18.0% |
| EPS (diluted) | $-0.81 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $0 | $26.0K | ||
| Q3 25 | $0 | $5.0K | ||
| Q2 25 | $0 | $5.0K | ||
| Q1 25 | $0 | $5.0K | ||
| Q4 24 | — | $5.0K | ||
| Q3 24 | — | $5.0K | ||
| Q2 24 | — | $5.0K | ||
| Q1 24 | — | $5.0K |
| Q4 25 | $-17.6M | — | ||
| Q3 25 | $-16.3M | $-19.0M | ||
| Q2 25 | $-14.4M | $-22.1M | ||
| Q1 25 | $-9.3M | $-19.6M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-22.8M | ||
| Q2 24 | — | $-24.6M | ||
| Q1 24 | — | $-24.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | -417180.0% | ||
| Q2 25 | — | -458440.0% | ||
| Q1 25 | — | -436300.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -495340.0% | ||
| Q2 24 | — | -534900.0% | ||
| Q1 24 | — | -535880.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | -380280.0% | ||
| Q2 25 | — | -442920.0% | ||
| Q1 25 | — | -391500.0% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -456900.0% | ||
| Q2 24 | — | -492800.0% | ||
| Q1 24 | — | -487880.0% |
| Q4 25 | $-0.81 | — | ||
| Q3 25 | $-0.75 | $-0.21 | ||
| Q2 25 | $-0.66 | $-0.27 | ||
| Q1 25 | $-0.71 | $-0.26 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.32 | ||
| Q2 24 | — | $-0.35 | ||
| Q1 24 | — | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $110.0M | $273.5M |
| Total DebtLower is stronger | — | $34.3M |
| Stockholders' EquityBook value | $106.6M | $224.9M |
| Total Assets | $117.2M | $279.9M |
| Debt / EquityLower = less leverage | — | 0.15× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $110.0M | $273.5M | ||
| Q3 25 | $126.3M | $210.8M | ||
| Q2 25 | $141.8M | $183.1M | ||
| Q1 25 | $151.3M | $149.8M | ||
| Q4 24 | — | $131.9M | ||
| Q3 24 | — | $139.4M | ||
| Q2 24 | — | $164.9M | ||
| Q1 24 | — | $182.0M |
| Q4 25 | — | $34.3M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $106.6M | $224.9M | ||
| Q3 25 | $122.4M | $185.6M | ||
| Q2 25 | $136.9M | $161.4M | ||
| Q1 25 | $150.7M | $142.2M | ||
| Q4 24 | — | $123.5M | ||
| Q3 24 | — | $133.4M | ||
| Q2 24 | — | $152.5M | ||
| Q1 24 | — | $172.9M |
| Q4 25 | $117.2M | $279.9M | ||
| Q3 25 | $133.2M | $218.4M | ||
| Q2 25 | $147.5M | $190.3M | ||
| Q1 25 | $157.0M | $157.3M | ||
| Q4 24 | — | $139.3M | ||
| Q3 24 | — | $147.9M | ||
| Q2 24 | — | $173.3M | ||
| Q1 24 | — | $188.4M |
| Q4 25 | — | 0.15× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-16.8M | $-67.5M |
| Free Cash FlowOCF − Capex | — | $-67.5M |
| FCF MarginFCF / Revenue | — | -259792.3% |
| Capex IntensityCapex / Revenue | — | 42.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-16.8M | $-67.5M | ||
| Q3 25 | $-16.1M | $-11.9M | ||
| Q2 25 | $-9.8M | $-19.4M | ||
| Q1 25 | $-11.4M | $-16.8M | ||
| Q4 24 | — | $-79.8M | ||
| Q3 24 | — | $-27.1M | ||
| Q2 24 | — | $-18.1M | ||
| Q1 24 | — | $-16.4M |
| Q4 25 | — | $-67.5M | ||
| Q3 25 | $-16.1M | — | ||
| Q2 25 | $-9.9M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -259792.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | 42.3% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
